Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate the safety of SU011248 in combination with paclitaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel; Sunitinib

Criteria

Inclusion Criteria:

• Breast cancer with evidence of unresectable, locally recurrent or metastatic disease.

• Candidate for treatment with paclitaxel.

Exclusion Criteria:

• Prior chemotherapy in the advanced disease setting.

• HER2 positive disease unless previously treated with trastuzumab.